Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.67 |
| ▸ | HTR2A | P28223 | 13/20 | 0.67 |
| ▸ | HTR2B | P41595 | 13/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361508 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL5356715 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL7149618 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL5356719 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL7151742 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL5356369 | 0.81 | HTR2A (1.00) | HTR2CHTR2AHTR2B | |
| SCHEMBL7163478 | 0.81 | HTR2A (1.00) | HTR2CHTR2AHTR2B | |
| SCHEMBL5363433 | 0.81 | HTR2A (1.00) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL5358949 | 0.80 | HTR2A (0.97) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL5359144 | 0.80 | HTR2A (0.97) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | GPR119, INSR, IRS1 | HTR2C 65/4885HTR2A 78/4885HTR2B 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.